Chemotherapy. Encounter for antineoplastic chemotherapy
Conditions
Interventions
Intervention 1: Intervention group: received livergol tablet produced by Goldarou Co. (140 mg ) once a day for three months. Intervention 2: Control group: received placebo tablet produced by Goldaro
Sponsors
Zanjan University of Medical Sciences
Goldaru Pharmaceutical Company
Eligibility
Sex/Gender
All
Age
35 Years to 75 Years
Inclusion criteria
Inclusion criteria: Age range 35-75 years Patients with cancers receiving oxaliplatin, cisplatin or paclitaxel-based chemotherapy regimens Patients with concussions admitted to Valiasr educational center or referred to Valiasr Oncology Clinic
Exclusion criteria
Exclusion criteria: Liverpool contraindication The presence of peripheral peripheral neuropathy continues to be the treatment that needs to be changed with chemotherapy regimens Other underlying etiologies of neuropathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the effect of Levergol on the outcome of neuropathy in patients with concussion undergoing chemotherapy with oxaliplatin and paclitaxel. Timepoint: three months. Method of measurement: FACT/GOG-NTX. | — |
Secondary
| Measure | Time frame |
|---|---|
| Determination of quality of life in livergol recipient group. Timepoint: three months. Method of measurement: FACT/GOG-NTX. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Hamed Ghavimi
Zanjan University of Medical Sciences
Outcome results
None listed